Date:8/6/2009

r current assets 2,383 1,311 ----- ----- Total current assets 85,372 122,284 Property, equipment and leasehold improvements, net 11,762 9,195 Long-term marketable securities 5,710 5,748 Goodwill 10,007 2,398 Other long-term assets 974 859 --- --- Total assets $113,825 $140,484 ======== ======== Liabilities and Stockholders' Equity: Accounts payable $7,858 $8,321 Accrued expenses 7,999 8,170 Deferred revenue 1,785 1,444 Other current liabilities 521 456 Short-term debt 1,304 647 ----- --- Total current liabilities 19,467 19,038 Long-term liabilities 6,844 5,233 Stockholders' equity 87,514 116,213 ------ ------- Total liabilities and stockholders' equity $113,825 $140,484 ======== ========

'/>"/>

SOURCE SEQUENOM, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10
Related biology technology :

1. SEQUENOM Announces Launch of MassARRAY Compact 96 System
2. SEQUENOM to Hold First Quarter 2009 Financial Results Conference Call on April 30
3. Webcast Alert: Sequenom: Defining the Future of Noninvasive Prenatal Diagnostics
4. Sequenom to Webcast Analyst and Investor Briefing Presentation on June 3
5. Sequenom to Webcast Analyst and Investor Briefing Presentation on September 24
6. OncoGenex Reports Second Quarter 2009 Financial Results
7. Repligen Reports First Quarter Fiscal Year 2010 Financial Results
8. PDI Reports 2009 Second Quarter Financial Results
9. Cadence Pharmaceuticals Reports Second Quarter 2009 Financial Results
10. Optimer Pharmaceuticals Reports Second Quarter 2009 Financial Results
11. NxStage Reports Second Quarter 2009 Financial Results